WATERTOWN, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation, including an update on its eravacycline development program, at the Stifel 2015 Healthcare Conference on November 17, 2015 at 8:00 a.m. Eastern Time at The New York Palace Hotel in New York City.

A live audio webcast of the Stifel presentation will be available on the company's website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 90 days.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes its lead clinical candidate eravacycline, a broad-spectrum intravenous and oral antibiotic, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
CONTACT: Investor Contacts:         Tetraphase Pharmaceuticals         Teri Dahlman         617-600-7040         tdahlman@tphase.com                  Argot Partners         Susan Kim         212-600-1902         susan@argotpartners.com                  Media Contact:         Sam Brown Inc.         Mike Beyer         312-961-2502         mikebeyer@sambrown.com

Tetraphase Logo